Previous studies have demonstrated that low doses of fractionated radiotherapy (RT) also significantly improve CD8+ T cell-mediated tumor remission, particularly in combination with anti-PD-1 or anti-PD-L1 therapies [17–19]. This evidence concerns the gene CD8A and neoplasm.